-
公开(公告)号：US06827943B2
公开(公告)日：2004-12-07
申请号：US10328368
申请日：2002-12-23
IPC分类号： A61K600
CPC分类号： A61Q19/00 , A61K8/19 , A61K8/27 , A61K8/42 , A61K31/17 , A61K31/28 , A61K31/30 , A61K31/32 , Y10S514/844 , A61K2300/00
摘要： Described are dermatological compositions for treating, protecting and re-epitheliazing cutaneous wounds and damaged skin, such compositions including about 21 to about 40% urea and trace amounts of zinc, copper and manganese in the form of their respective pharmaceutically acceptable salts.
-
132.发明申请Methods of preventing and treating SARS using low pH respiratory tract compositions 审中-公开使用低pH呼吸道组合物预防和治疗SARS的方法公开(公告)号：US20040234457A1
公开(公告)日：2004-11-25
申请号：US10770138
申请日：2004-02-02
IPC分类号： A61L009/04 , A61K009/14 , A61K033/24
CPC分类号： A61K45/06 , A01N43/36 , A61K9/0043 , A61K31/19 , A61K31/28 , A61K31/315 , A61K33/24 , A61K33/30 , D21H21/36 , D21H27/32 , A61K2300/00 , A01N2300/00
摘要： The present invention is directed to methods of preventing and treating Severe Acute Respiratory Syndrome (SARS) by the administration of respiratory tract compositions having low pH values. The respiratory tract compositions have a pH of from about 3.0 to about 5.5, and are preferably administered to areas of the respiratory tract such as the nasal cavity to effectively prevent and treat respiratory tract viral infections, particularly SARS. The respiratory tract compositions comprise an organic acid in combination with a metal compound.
摘要翻译： 本发明涉及通过施用具有低pH值的呼吸道组合物来预防和治疗严重急性呼吸综合征（SARS）的方法。 呼吸道组合物的pH为约3.0至约5.5，并且优选施用于呼吸道如鼻腔的区域，以有效预防和治疗呼吸道病毒感染，特别是SARS。 呼吸道组合物包含与金属化合物组合的有机酸。
-
133.发明申请Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto 审中-公开铜依赖性非传统促炎细胞因子出口及其相关的方法，组合物和试剂盒公开(公告)号：US20040229796A1
公开(公告)日：2004-11-18
申请号：US10786223
申请日：2004-02-23
发明人： Thomas Maciag , Anna Mandinova , Lazar Mandinov , Igor Prudovsky , Stephen Bellum , Raffaella Soldi , Cinzia Bagala
IPC分类号： A61K038/17 , A61K031/555 , A61K031/195
CPC分类号： G01N33/6863 , A61K31/195 , A61K31/28 , A61K31/355 , A61K33/34 , A61K38/1738 , A61K45/06 , G01N33/6869 , G01N2333/545 , G01N2500/10
摘要： The present invention relates to the discovery that non-traditional export of certain pro-inflammatory cytokines lacking a signal sequence from a cell can be inhibited by copper chelation and/or administration to the cell of a truncated form of S100A13 lacking the basic residue portion. Further, copper chelation inhibits, inter alia, neointima formation, macrophage infiltration and associated inflammation, cell proliferation, secretion of extracellular matrix, intimal thickening, adventitial angiogenesis, restenosis, and the like, associated with vascular vessel injury. Thus, the present invention provides novel methods of preventing and treating, and for identifying novel compounds also useful as therapeutics for, such conditions.
摘要翻译： 本发明涉及以下发现：通过对缺乏碱性残基部分的S100A13截短形式的细胞进行铜螯合和/或给药，可以抑制某些缺乏来自细胞的信号序列的促炎细胞因子的非传统出口。 此外，铜螯合尤其抑制与血管损伤相关的新内膜形成，巨噬细胞浸润和相关炎症，细胞增殖，分泌细胞外基质，内膜增厚，外膜血管生成，再狭窄等。 因此，本发明提供了预防和治疗以及用于鉴定也可用作这些病症的治疗剂的新化合物的新方法。
-
134.发明申请Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration 审中-公开红细胞生成素给药的药代动力学和药效学建模公开(公告)号：US20040176297A1
公开(公告)日：2004-09-09
申请号：US10807451
申请日：2004-03-24
发明人： Wing Cheung , David Gibson , Christine Cote , Els Vercammen
IPC分类号： A61K038/18 , G01N033/48 , G01N033/50 , A61K033/24
CPC分类号： G16C20/30 , A61K38/00 , A61K38/1816 , G16H50/50 , A61K38/14 , A61K33/24 , A61K31/70 , A61K31/505 , A61K31/475 , A61K31/28 , A61K2300/00
摘要： The present invention relates to systems and methods for obtaining optimized EPO dosage regimens for a desired pharmacodynamic/pharmacokinetic response. The system includes choosing one or more EPO dosage regimens, then using a PK/PD model to determine the pharmacodynamic/pharmacokinetic profile of one or more EPO dosage regimens, and finally selecting one of the EPO dosage regimens for administration to achieve the desired pharmacodynamic/pharmacodynamic response based on the EPO profile.
摘要翻译： 本发明涉及用于获得所需药效学/药代动力学反应的优化EPO剂量方案的系统和方法。 该系统包括选择一种或多种EPO剂量方案，然后使用PK / PD模型来确定一种或多种EPO剂量方案的药效学/药代动力学特征，最后选择用于给药的一种EPO剂量方案以达到所需的药效/ 基于EPO谱的药效学反应。
-
公开(公告)号：US20040138121A1
公开(公告)日：2004-07-15
申请号：US10691915
申请日：2003-10-23
发明人： Anil Gulati
IPC分类号： A61K038/17 , A61K031/519
CPC分类号： A61K31/00 , A61K31/28 , A61K31/337 , A61K31/4745 , A61K31/519 , A61K31/704 , A61K33/24 , A61K35/60 , A61K38/05 , A61K38/2013 , A61K38/208 , A61K38/21 , A61K38/2285 , A61K41/0038 , A61K45/06 , A61N2005/1098 , A61K2300/00
摘要： Compositions and methods of preventing or treating a breast cancer are disclosed. The composition and method can utilize an endothelin B agonist and a chemotherapeutic agent as active ingredients to treat a solid tumor in mammals, including humans. Alternatively, the composition and method can utilize an endothelin B antagonist and an optional angiogenesis inhibitor to treat a solid tumor in mammals, including humans.
摘要翻译： 公开了预防或治疗乳腺癌的组合物和方法。 组合物和方法可以利用内皮素B激动剂和化学治疗剂作为活性成分来治疗包括人在内的哺乳动物的实体肿瘤。 或者，组合物和方法可以利用内皮素B拮抗剂和任选的血管生成抑制剂来治疗包括人在内的哺乳动物的实体肿瘤。
-
公开(公告)号：US20040126433A1
公开(公告)日：2004-07-01
申请号：US10734784
申请日：2003-12-12
发明人： David Parsons , Elizabeth Jacques , Philip Bowler
IPC分类号： A61K033/38 , A61L015/00
CPC分类号： A61L31/16 , A61K31/28 , A61K31/74 , A61K33/38 , A61L15/44 , A61L26/0066 , A61L27/54 , A61L29/16 , A61L2300/102 , A61L2300/104 , A61L2300/404 , A61L2300/45 , A61K2300/00
摘要： Methods of enhancing the photostabilizing of silver in medical materials are described. More particularly, the methods increase the photostabilization of silver in certain materials comprising hydrophilic, amphoteric and anionic polymers by subjecting the polymers to solutions containing an organic solvent and silver, during or after which one or more agents are added which facilitate the photostablization of the material.
摘要翻译： 描述了增强医疗材料中银的光稳定性的方法。 更具体地说，这种方法通过使聚合物经受有机溶剂和银的溶液使某些包含亲水性，两性和阴离子聚合物的材料的光稳定化增加，在此期间或之后，加入一种或多种促进材料光稳定化的试剂 。
-
公开(公告)号：US20040122087A1
公开(公告)日：2004-06-24
申请号：US10328368
申请日：2002-12-23
IPC分类号： A61K031/32 , A61K031/28 , A61K031/30 , A61K031/17
CPC分类号： A61Q19/00 , A61K8/19 , A61K8/27 , A61K8/42 , A61K31/17 , A61K31/28 , A61K31/30 , A61K31/32 , Y10S514/844 , A61K2300/00
摘要： Described are dermatological compositions for treating, protecting and re-epitheliazing cutaneous wounds and damaged skin, such compositions including about 21 to about 40% urea and trace amounts of zinc, copper and manganese in the form of their respective pharmaceutically acceptable salts.
摘要翻译： 描述了用于治疗，保护和重新上皮皮肤伤口和受损皮肤的皮肤病学组合物，所述组合物包括其各自的药学上可接受的盐形式的约21至约40％的尿素和痕量的锌，铜和锰。
-
公开(公告)号：US06723712B2
公开(公告)日：2004-04-20
申请号：US10138999
申请日：2002-05-02
申请人： Jean Bourhis , Bassam Abdulkarim , Eric Deutsch
发明人： Jean Bourhis , Bassam Abdulkarim , Eric Deutsch
IPC分类号： A61N3675
CPC分类号： A61K31/675 , A61K33/24 , A61K45/06 , Y02A50/467 , A61K31/28 , A61K2300/00
摘要： The invention relates to an antiviral agent for use in combination with an anticancer agent, for the treatment of cancer. Especially, the invention provides means for the treatment of non-virus-associated cancer.
-
公开(公告)号：US06703050B1
公开(公告)日：2004-03-09
申请号：US09389435
申请日：1999-09-03
IPC分类号： A61K3334
CPC分类号： A61K31/28 , A61K33/24 , A61K33/34 , A61K45/06 , A61K2300/00
摘要： Provided are agents that can bind to copper, and form a tripartite complex with protein, and the use of these agents in the prevention and treatment of diseases with a vascular component, such as solid tumors. Compositions and methods for combination therapy of these diseases, including cancer, as well as therapeutic kits, are also provided.
摘要翻译： 提供可以与铜结合并与蛋白质形成三方络合物的试剂，以及这些试剂在预防和治疗诸如实体瘤的血管成分的疾病中的用途。 还提供了用于这些疾病（包括癌症）以及治疗试剂盒的组合治疗的组合物和方法。
-
公开(公告)号：US20030236228A1
公开(公告)日：2003-12-25
申请号：US10400265
申请日：2003-03-27
IPC分类号： A61K031/69 , A61K031/4706 , A61K031/445 , A61K031/366 , A61K031/13
CPC分类号： A61K31/662 , A61K31/00 , A61K31/13 , A61K31/165 , A61K31/198 , A61K31/28 , A61K31/35 , A61K31/352 , A61K31/4015 , A61K31/42 , A61K31/425 , A61K31/426 , A61K31/437 , A61K31/4412 , A61K31/4465 , A61K31/454 , A61K31/47 , A61K31/498 , A61K31/505 , A61K31/5513 , A61K31/675 , A61K31/69
摘要： The present invention relates generally to pharmacological methods for the prevention or amelioration of sleep-related breathing disorders via administration of agents or combinations of agents that possess glutamate-related and/or glycine-related pharmacological activity or that modulate the release of glutamate, glycine, or both from nerve terminals with the central nervous system.
摘要翻译： 本发明一般涉及通过施用具有谷氨酸相关和/或甘氨酸相关药理学活性的试剂或试剂组合来预防或改善睡眠相关呼吸障碍的药理学方法，或调节谷氨酸，甘氨酸， 或两者来自具有中枢神经系统的神经末梢。
-
-
-
-
-
-
-
-
-
搜索结果
1148 条记录 (耗时 0.049 秒)
